Terms: = Liver cancer AND TPM4, P67936, 7171, ENSG00000167460
5 results:
1. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.
Yang CT; Yao WY; Yang CY; Peng ZY; Ou HT; Kuo S
J Intern Med; 2024 Mar; 295(3):357-368. PubMed ID: 37994187
[TBL] [Abstract] [Full Text] [Related]
2. Cytoskeleton remodeling mediated by circRNA-YBX1 phase separation suppresses the metastasis of liver cancer.
Liu B; Shen H; He J; Jin B; Tian Y; Li W; Hou L; Zhao W; Nan J; Zhao J; Shen J; Yu H; Wang Y; Shan G; Shi L; Cai X
Proc Natl Acad Sci U S A; 2023 Jul; 120(30):e2220296120. PubMed ID: 37459535
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and tpm4.
Yan J; Xie B; Tian Y; An W; Peng Z; Liu Z; Li J; Li L
BMC Cancer; 2023 Jun; 23(1):557. PubMed ID: 37328795
[TBL] [Abstract] [Full Text] [Related]
4. The expression and clinical significance of tpm4 in hepatocellular carcinoma.
Li L; Ye T; Zhang Q; Li X; Ma L; Yan J
Int J Med Sci; 2021; 18(1):169-175. PubMed ID: 33390785
[TBL] [Abstract] [Full Text] [Related]
5. tpm4 aggravates the malignant progression of hepatocellular carcinoma through negatively regulating SUSD2.
Sheng ZG; Chen MH
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4756-4765. PubMed ID: 32432739
[TBL] [Abstract] [Full Text] [Related]
